Frequency of HIV-1 viral load monitoring of patients initially successfully treated with combination antiretroviral therapy

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Romih, Vanja ^a   Lepej, Snježana Židovec ^a   Gedike, Kornelija ^a   Lukas, Davorka ^a   Begovac, Josip ^a,b  

^a Ministarstva Zdravstva i Socijalne Skrbi RH   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; COMBINATION ANTIRETROVIRAL THERAPY; DEMOGRAPHY; DRUG COMBINATION; DRUG MONITORING; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATIENT MONITORING; SOCIAL ASPECT; STATISTICAL MODEL; TREATMENT DURATION; VIRUS LOAD; CROATIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; MIDDLE AGED; TIME; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTI-HIV AGENTS; CROATIA; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); TIME FACTORS; VIRAL LOAD;

EID: 78649665261     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015051     Document Type: Article

References (14)

1. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, et al. (2010) Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375: 123-131.
2. Begovac J, Zekan A, Skoko-Poljak D (2006) Twenty years of human immunodeficiency virus infection in Croatia-an epidemic that is still in an early stage. Coll Antropol 30 Suppl 2: 17-23.
3. Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, et al. (2008) Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS 22: 2381-2390.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents (2009) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available: http://www.aidsinfo.nih.gov/Guidelines/. Accessed 15 August 2010.
5. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
6. Ramirez-Piedad MK, Lepej SZ, Yerly S, Begovac J (2009) High prevalence of non-B HIV-1 subtypes in seamen and their sexual partners in Croatia. J Med Virol 81: 573-577.
7. Bozicevic I, Rode OD, Lepej SZ, Johnston LG, Stulhofer A, et al. (2009) Prevalence of sexually transmitted infections among men who have sex with men in Zagreb, Croatia. AIDS Behav 13: 303-309.
8. Haubrich RH, Currier JS, Forthal DN, Beall G, Kemper CA, et al. (2001) A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. Clin Infect Dis 33: 1060-1068.
9. Raboud JM, Loutfy MR, Su D, Bayoumi AM, Klein MB, et al. (2010) Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries. BMC Infect Dis 10: 40.
10. Raboud JM, Abdurrahman ZB, Major C, Millson P, Robinson G, et al. (2005) Nonfinancial factors associated with decreased plasma viral load testing in Ontario, Canada. J Acquir Immune Defic Syndr 39: 327-332.
11. Laine C, Zhang D, Hauck WW, Turner BJ (2002) HIV-1 RNA viral load monitoring in HIV-infected drug users on antiretroviral therapy: relationship with outpatient care patterns. J Acquir Immune Defic Syndr 29: 270-274.
12. Kendall MA, Andersen JW, van der Horst C (2006) A reduced frequency visit schedule underreports adverse events that resulted in dose modifications or treatment discontinuations in HIV/AIDS clinical trials: ACTG DACS 207. Contemp Clin Trials 27: 287-294.
13. Bernays S, Rhodes T (2009) Experiencing uncertain HIV treatment delivery in a transitional setting: qualitative study. AIDS Care 21: 315-321.
14. Tesic V, Kolaric B, Begovac J (2006) Attitudes towards HIV/AIDS among four year medical students at the University of Zagreb Medical School-better in 2002 than in 1993 but still unfavorable. Coll Antropol 30 Suppl 2: 89-97.